levofloxacin has been researched along with Disease Models, Animal in 110 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (4.55) | 18.2507 |
| 2000's | 47 (42.73) | 29.6817 |
| 2010's | 48 (43.64) | 24.3611 |
| 2020's | 10 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Cottagnoud, M; Cottagnoud, P; Schaffner, T; Stucki, A; Winkelmann, V | 1 |
| Clark, KP; Griffith, ME; Hawley, JS; Hospenthal, DR; Johnson, EN; Moon, JE; Murray, CK | 1 |
| Landmann, R; Murphy, CK; Rothstein, DM; Trampuz, A; Widmer, AF; Zimmerli, W | 1 |
| Deziel, MR; Drusano, GL; Liu, W; Louie, A | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Fujimoto, K; Hirokawa, Y; Kashimoto, S; Kato, S; Kinoshita, H; Kitadai, N; Kojima, T; Nakata, K; Tanaka, T | 1 |
| Laohavaleeson, S; Nicolau, DP; Tessier, PR | 1 |
| Drusano, GL; Fregeau, C; Kulawy, R; Liu, W; Louie, A | 1 |
| Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K | 1 |
| Basarab, GS; Bist, S; Boriack-Sjodin, PA; Dangel, B; Eakin, AE; Illingworth, R; Manchester, JI; Sherer, BA; Sriram, S; Uria-Nickelsen, M | 1 |
| Alm, R; Basarab, GS; Bist, S; Dangel, PB; Eakin, AE; Garner, CE; Green, O; Hauck, S; Hill, PJ; Hull, K; Illingworth, R; Manchester, JI; Rooney, M; Sherer, BA; Uria-Nickelsen, M; Zhou, F | 1 |
| Cui, S; Ding, K; Franzblauc, SG; Lu, X; Tang, J; Wan, B; Zhang, T; Zhang, X | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Crumrine, M; Hewitt, JA; Slay, RM | 1 |
| Han, H; Li, FX; Qin, XH; Wang, XL; Wu, DQ; Yu, JY; Zhang, FF; Zhu, J | 1 |
| Andremont, A; Burdet, C; Corbel, T; de Gunzburg, J; Ferreira, S; Mentré, F; Nevière, A; Pulse, M; Sablier-Gallis, F; Saint-Lu, N; Sayah-Jeanne, S; Weiss, W | 1 |
| Jiang, M; Li, G; Wu, X; Xu, L | 1 |
| Abd Eldaim, MA; Abdallah, AEM; Abdel-Daim, MM; Abdelaziz, SAM; Abdul Rashid, S; Abdullah, AS; Abdullah, LC; Abramson, MJ; Ahmed, HB; Ahmed, MM; Ahn, YC; Alexander, DC; Ando, T; Angelone, AM; Anglani, F; Ap, Y; Arthanari, SK; Axelrad, C; Bai, S; Bakonyi, P; Barnes, E; Beckmann, NA; Bélafi-Bakó, K; Bennett, CM; Bestha, RM; Bitsch, RG; Bradley, CA; Bu, Y; Calò, LA; Cañedo-Villaroya, E; Carlson, L; Caruso, S; Casado-Flores, J; Ceol, M; Cesarino, I; Chen, IL; Chen, R; Chen, X; Chilvers, MI; Cho, WK; Choong, TSY; Conceição-Neto, N; Culver, EL; Dai, X; de Lama Caro-Patón, G; De Rosa, I; Del Prete, D; Dharmage, SC; Dimitriadis, E; Dittakavi, S; Dobrowolski, JC; Edin, S; Elgarawany, GE; Emam, HE; Emmens, RW; Erbas, B; Erwich, JJHM; Farghali, M; Feng, L; Funston, RN; Gabler, NK; Gale, P; Ganesh, M; Gao, J; Gao, L; Gao, X; García-Salido, A; Gatto, R; Gautam, S; Ge, C; Ghogomu, SM; Gianesello, L; Gonçales, VR; Gooch, JL; Gooding, JJ; Gourley, GG; Gu, H; Gu, X; Gu, Z; Guerreri, M; Guillén, M; Hazzaa, SM; Heylen, E; Hicks, R; Hong, X; Hoshi, M; Hu, B; Hu, LX; Hu, R; Hu, S; Huang, J; Huang, K; Hubbard, WB; Hui, J; Hwang, NY; Iannacci, J; Ianus, A; Iglesias-Bouzas, MI; Ihara, I; Iwasaki, M; Jaeger, S; Kandel, YR; Karpińska, G; Kim, HK; Klopfenstein, TJ; Knorr, D; Koók, L; Kotb, S; Kruithof, S; Larsson, P; Laurence, C; Leng, J; Li, H; Li, J; Li, Q; Li, S; Li, X; Li, Z; Lian, J; Liang, JX; Liang, X; Lighaam, LC; Lin, CW; Lin, HC; Lin, J; Ling, A; Liu, J; Liu, P; Liu, YS; Ljuslinder, I; Lo, GH; Lodge, CJ; Löfgren-Burström, A; Lowe, AJ; Lu, M; Lu, N; Lucero-Prisno, DE; Luebbe, KM; Luo, X; Ma, Z; Maes, P; Makuch, M; Malekbala, MR; Mao, Z; Martínez-Romera, I; Marzo, G; Mathew, FM; Mattei, A; Matthijnssens, J; Mayumi, M; Morita, N; Mueller, DS; Mullangi, R; Mummolo, S; Murthi, P; Myte, R; Nabeshima, T; Nakamoto, K; Nehdi, IA; Nemestóthy, N; Niessen, HWM; Noh, JM; Nota, A; Nunes, D; Oh, D; Öhlund, D; Olsen, KM; Ono, H; Osawa, Y; Palmqvist, R; Palombo, M; Park, M; Patience, JF; Peng, Y; Perng, DS; Persano, A; Priante, G; Prince, SJ; Pulipati, S; Pyo, H; Qiu, X; Quan, J; Quaranta, F; Quinzi, V; Rademacher, CJ; Rajaraman, G; Rashid, U; Rauch, JC; Rector, A; Remmerswaal, EBM; Ren, R; Rispens, T; Rocha, GS; Saad, NM; Saito, K; Salamova, A; Sarfaraz, K; Satoshi, A; Schnellmann, RG; Scholpa, NE; Schonhoff, M; Schwartz, KJ; Schwarze, M; Schweer, WP; Seiichi, Y; Serrano-González, A; Severino, J; Shemesh, N; Shi, ZQ; Shike, DW; Shim, YM; Siciliano, PA; Siebenrock, KA; Silva, MKL; Smith, DL; Soltani, S; Song, YM; Spry, ML; Stalker, LA; Stokes, RS; Sullivan, PG; Sun, JM; Sun, S; Svanes, C; Syo, K; Tai, CM; Takashima, S; Tashita, C; Taurino, A; Ten Berge, IJM; Tenuta, AU; Teo, SH; Tilley, RD; Trivedi, RK; Umetsu, K; Unger, PA; van Bruggen, R; van Ham, SM; Van Ranst, M; Vanitha, J; Vekaria, HJ; Venier, M; Venkateshwaran, K; Venkert, A; Vermeulen, E; Wan, C; Wang, H; Wang, N; Wang, P; Wang, T; Wang, X; Wang, Y; Wise, KA; Wolbink, GJ; Wu, J; Wu, P; Wu, S; Wu, Y; Xia, Q; Xin, W; Xiong, Q; Xu, H; Xu, P; Xue, S; Yamamoto, Y; Yamashiro, T; Yan, F; Yan, H; Yan, S; Yan, Y; Yang, JM; Yang, L; Yang, P; Ye, W; Yeh, JH; Yinda, CK; Ying, GG; Ying, L; Yoon, HG; Yu, H; Zainuddin, M; Zakkula, A; Zeller, M; Zeng, Y; Zha, J; Zhang, F; Zhang, H; Zhang, M; Zhang, Q; Zhang, S; Zhang, T; Zhang, Z; Zhao, C; Zhao, J; Zhao, Y; Zhong, Q; Zhu, J; Zingmark, C; Zo, JI; Zou, Y | 1 |
| Campbell, JL; Hewitt, JA; Lanning, LL | 1 |
| Campbell, JL; Fay, MP; Hewitt, JA; Lanning, LL | 1 |
| Abdelaziz, AA; El-Barrawy, MA; El-Nagar, RAM | 1 |
| Chen, K; Qiu, J; Wang, W; Zheng, S; Zhu, J | 1 |
| Chang, YF; Cheng, YH; Ko, YC; Liu, CJ | 1 |
| Bate, PNN; Chiwala, G; Fang, C; Guan, P; Hameed, HMA; Hu, J; Khan, SA; Liu, J; Liu, Z; Mugweru, JN; Tan, S; Tan, Y; Wang, B; Yusuf, B; Zhang, T; Zhong, N | 1 |
| Aubry, A; Bernard, C; Chauffour, A; Chavanet, P; El Helali, N; Jarlier, V; Maitre, T; Petitjean, G; Reibel, F; Veziris, N | 1 |
| Monogue, ML; Nicolau, DP | 1 |
| Ghazi, IM; Monogue, ML; Nicolau, DP; Tsuji, M | 1 |
| Bar-David, E; Ben-Shmuel, A; Brosh, T; Glinert, I; Kobiler, D; Levy, H; Schlomovitz, J; Sittner, A; Weiss, S | 1 |
| Farid, AS; Hegazy, AM | 1 |
| Bratchikov, OI; Dubonos, PA; Tyuzikov, IA | 1 |
| Briales, A; Díaz-de-Alba, P; Docobo-Pérez, F; Domínguez-Herrera, J; López-Rojas, R; Pachón, J; Pascual, A; Pichardo, C; Rodríguez-Baño, J; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Ahmad, Z; Grosset, JH; Minkowski, A; Nuermberger, EL; Peloquin, CA; Tyagi, S | 1 |
| Albrecht, MT; Dreier, TM; Houchens, CR; Larsen, JC; Smith, AP; Stundick, MV | 1 |
| Amado, V; Gaio, E; Huang, W; Melo-Silva, CA; Rangel, L; Storck, R | 1 |
| Cui, J; Ni, W; Song, X | 1 |
| Crandon, JL; Nicolau, DP; Nordmann, P; Wiskirchen, DE | 1 |
| Ao, H; Gu, J; Li, C; Mao, X; Yang, X | 1 |
| Lee, WH; Li, SA; Liu, J; Wang, YJ; Xiang, Y; Zhang, Y | 1 |
| Fujita, K; Goto, H; Hattori, T; Ito, N; Koike, N; Kumakura, S; Kuroda, M; Matsumoto, T; Miyake, T; Tajima, K; Yamaguchi, T | 1 |
| Guo, C; Han, S; Jiang, H; Liu, T; Wu, X | 1 |
| Adhikary, R; Bhattacharyya, A; Bishayi, B; Mahanti, S; Majhi, A | 1 |
| Comer, J; Kammanadiminti, S; Kodihalli, S; Meister, G; Patnaikuni, RK; Sinclair, C | 1 |
| Baluya, D; Brown, D; Drusano, GL; Fikes, S; Jelliffe, R; Kurhanewicz, S; Liu, W; Louie, A; Neely, MN; Robbins, N; Schumitzky, A; VanGuilder, M | 1 |
| Bolduc, DL; Elliott, TB; Fatanmi, OO; Kiang, JG; Ledney, GD; Newman, VL; Romaine, PL; Singh, VK; Wise, SY | 1 |
| Ariza, J; Cabellos, C; Cabo, J; El Haj, C; Garcia-Somoza, D; Murillo, O; Ribera, A; Tubau, F; Vivas, M | 1 |
| Fukuda, M; Sasaki, H | 1 |
| Ehara, T; Fujita, K; Goto, H; Hattori, T; Koike, N; Kumakura, S; Kuroda, M; Matsumoto, T; Nakagawa, H; Takahashi, H | 1 |
| Fujita, K; Goto, H; Hattori, T; Ito, N; Koike, N; Kuroda, M; Matsumoto, T; Miyake, T; Tajima, K; Takahashi, H | 1 |
| Ohashi, Y; Suzuki, T; Yamamoto, T | 1 |
| Atkins, HS; Flick-Smith, HC; Hall, CA; Harding, SV; Titball, RW | 1 |
| Ehara, T; Goto, H; Hattori, T; Koike, N; Kumakura, S; Matsumoto, T; Nakagawa, H; Narimatsu, A | 1 |
| Hoshino, K; Kohno, S; Kurosaka, Y; Morinaga, Y; Nagaoka, K; Yanagihara, K | 1 |
| Chen, C; Gu, H; He, X; Huang, W; Jiang, J; Li, J; Liu, W; Wang, Q; Zhang, D; Zhou, N | 1 |
| Fantin, B; Massias, L; Muller-Serieys, C; Saleh Mghir, A | 1 |
| Ariza, J; Cabellos, C; Cabo, J; Carreras, M; Euba, G; Gudiol, F; Murillo, O; Pachón, ME; Verdaguer, R | 1 |
| Anisimov, BI; Ryzhko, IV; Trishina, AV; Tsuraeva, RI | 1 |
| Fujikawa, K; Karibe, Y; Kashimoto, Y; Kurosaka, Y; Namba, K; Otani, T; Uoyama, S; Yamaguchi, K | 1 |
| Azzopardi, K; Finnin, B; Graichen, F; Hart, E; Jeffery, J; Mayadunne, R; Nijagal, B; O'Leary, S; O'Shea, M; Robins-Browne, R; Taing, H; Tait, R; Watkinson, R; Wickramaratna, M | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Shanks, RM | 1 |
| Chen, H; Jiang, HR; Wu, XG; Xin, M; Yang, LN | 1 |
| Ishii, Y; Kimura, S; Sato, T; Tateda, K; Yamaguchi, K | 1 |
| Barr, EB; Brasel, TL; Gigliotti, AP; Koster, F; Layton, RC; McDonald, JD; Mega, W | 1 |
| Chen, X; Guo, X; Shi, G; Wang, H; Wang, S; Zhang, X | 1 |
| Bugaenko, SE; Elistratova, NA; Maliev, BM; Mozhokina, GN; Sokolova, GB; Solov'eva, IP | 1 |
| Ergun, H; Köseoglu-Eser, O; Mamuk, S; Melli, M; Saribas, Z | 1 |
| Inoko, H; Ishii, Y; Kimura, S; Kouyama, Y; Mitsunaga, S; Mori, N; Tateda, K; Yamaguchi, K; Yoshihara, E | 1 |
| Bourdage, JS; Duchars, M; Fuerst, TR; Fusco, PC; Leffel, EK; Williamson, ED | 1 |
| Dong, LY; Jiang, Q; Wang, CY; Wu, CQ; Zhang, ZF | 1 |
| Chopra, AK; Erova, TE; Fitts, EC; Kirtley, ML; Kozlova, EV; Rosenzweig, JA; Sha, J; Tiner, BL; van Lier, CJ | 1 |
| Kawasaki, S; Mito, T; Ohashi, Y; Suzuki, T; Tasaka, Y; Uda, T; Uno, T | 1 |
| Bolmer, S; Chen, C; Corey, A; Fiscella, M; Meister, G; Migone, TS; Ward, C | 1 |
| Ahanou, A; Buisson, M; Chavanet, P; Croisier, D; Duong, M; Lequeu, C; Neuwirth, C; Nierlich, A; Piroth, L; Portier, H | 1 |
| Cirioni, O; D'Amato, G; Del Prete, M; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Saba, V; Scalise, G | 1 |
| Rubinstein, E | 1 |
| Hiramatsu, K; Hirata, N; Kadota, J; Kishi, K; Murakami, J; Nasu, M; Shibata, T; Yamasaki, T | 1 |
| Carpenter, TR; Kaufman, MB; McDonnell, PJ; Sarayba, MA; Sweet, PM; Taban, M; Tungsiripat, T | 1 |
| Acosta, F; Cottagnoud, M; Cottagnoud, P; Entenza, J; Flatz, L; Kühn, F; Stucki, A | 1 |
| Chuah, SK; Gollapudi, S; Thadepalli, H | 1 |
| Bast, DJ; Bell, D; Chen, X; de Azavedo, JC; Dresser, L; Low, DE; Mandell, LA; Saskin, R; Yue, M | 1 |
| Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D | 1 |
| Graff, JM; Kesler-Diaz, A; McDonnell, PJ; Osann, KE; Reiser, BJ; Sarayba, MA; Shamie, N; Sweet, PM; Taban, M | 1 |
| Felici, A; Guerrini, M; Marchetti, F; Piccoli, L | 1 |
| Caballero, AR; Dajcs, JJ; Johnston, KH; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Alou, L; del Carmen Ponte, M; Gracia, M; Huelves, L; López-Casla, MT; Martínez-Marín, C; Prieto, J; Sevillano, D; Soriano, F | 1 |
| Cho, D; Corcoran, E; Dudley, MN; Griffith, DC; Lee, A; Lofland, D; Lomovskaya, O | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| Ariza, J; Cabellos, C; Doménech, A; Garcia, A; Gudiol, F; Murillo, O; Tubau, F | 1 |
| Gómez Gómez, J; López Fornás, F; Lorente Salinas, I; Martínez García, F; Pérez Salmerón, J; Roldán Conesa, D; Ruiz Gómez, J; Segovia Hernández, M; Valdés Chávarri, M | 1 |
| Aguero-Rosenfeld, ME; Filozov, A; Kamer, RS; Liveris, D; Schwartz, I; Telford, SR; Utpat, S; Wang, G; Wormser, GP; Zentmaier, L | 1 |
| Bast, DJ; de Azavedo, JC; Dresser, L; Duncan, CL; Low, DE; Mandell, LA; Walker, SE | 1 |
| Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J | 1 |
| Cheng, GF; Gu, CQ; Hu, XY; Li, XM; Wang, DH; Zhou, Q; Zhou, SQ | 1 |
| Ganey, PE; Hopfensperger, MJ; Roth, RA; Shaw, PJ | 1 |
| Bao, D; Pulse, ME; Renick, PJ; Truong, TT; Weiss, WJ | 1 |
| Chang, ST; Chen, CC; Cheng, KC; Chuang, YC; Huang, HC; Shieh, CC; Yu, WL | 1 |
| Agar, SL; Baze, WB; Chauhan, S; Chopra, AK; Erova, TE; Fadl, AA; Foltz, SM; Klimpel, GR; Motin, VL; Olano, JP; Peterson, JW; Sha, J; Suarez, G; Wang, S | 1 |
| Cynamon, MH; Klemens, SP; Rogge, MC; Sharpe, CA | 1 |
| Izumi, K; Kawazoe, K; Mikamo, H; Sato, Y; Tamaya, T | 1 |
| Bornitz, F; Hof, H; Kretschmar, M; Nichterlein, T | 1 |
| Fujimoto, K; Mizuno, K; Nabeshima, T; Ohta, M; Osada, T; Sakurai, T; Yamamura, K | 1 |
| Bui, KQ; Nicolau, DP; Nightingale, CH; Onyeji, CO; Owens, RC; Quintiliani, R | 1 |
| Fujii, N; Hayashi, S; Isogai, E; Isogai, H; Kimura, K; Kubota, T; Ohtani, T; Sato, K | 1 |
| Higashiyama, Y; Hirakata, Y; Kadota, J; Kaneko, Y; Kohno, S; Kuroki, M; Maesaki, S; Miyazaki, Y; Ohno, H; Sawai, T; Tashiro, T; Tomono, K; Yanagihara, K | 1 |
| Bryskier, A; Carbon, C; Farinotti, R; Joly-Guillou, ML; Wolff, M | 1 |
| Bui, KQ; Mattoes, H; McNabb, J; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D; Zhong, M | 1 |
| Dash, AK; Destache, CJ; Larsen, C; Owens, H; Pakiz, CB | 1 |
| Fujii, N; Hayashi, S; Hirose, K; Isogai, E; Isogai, H; Kimura, K; Kubota, T; Oguma, K; Takeshi, K | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, W; Kasprzykowski, F; Mackiewicz, Z; Mocchegiani, F; Orlando, F; Paggi, AM; Saba, V; Scalise, G | 1 |
| Anderlik, P; Lengyel, J; Máthé, A; Rókusz, L; Rozgonyi, F; Szabó, D | 1 |
| Bisognano, C; Francois, P; Lew, DP; Schrenzel, J; Vaudaux, P | 1 |
2 review(s) available for levofloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Animal models for Francisella tularensis and Burkholderia species: scientific and regulatory gaps toward approval of antibiotics under the FDA Animal Rule.
Topics: Animals; Anti-Bacterial Agents; Burkholderia; Burkholderia Infections; Ciprofloxacin; Disease Models, Animal; Drug Approval; Francisella tularensis; Government Regulation; Levofloxacin; Tularemia; United States; United States Food and Drug Administration | 2013 |
1 trial(s) available for levofloxacin and Disease Models, Animal
108 other study(ies) available for levofloxacin and Disease Models, Animal
| Article | Year |
|---|---|
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
Topics: Animals; Anti-Bacterial Agents; Bacteriolysis; Ceftriaxone; Cell Wall; Cerebrospinal Fluid; Choline; Daptomycin; Disease Models, Animal; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Treatment Outcome; Tritium | 2007 |
Efficacy of fluoroquinolones against Leptospira interrogans in a hamster model.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Ciprofloxacin; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Doxycycline; Female; Fluoroquinolones; Gatifloxacin; Injections, Intraperitoneal; Leptospira interrogans; Leptospirosis; Levofloxacin; Mesocricetus; Ofloxacin; Serotyping; Survival Analysis | 2007 |
Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Foreign-Body Reaction; Guinea Pigs; Injections, Intraperitoneal; Levofloxacin; Male; Microbial Sensitivity Tests; Molecular Structure; Ofloxacin; Rifampin; Rifamycins; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2007 |
Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Bacterial; Humans; Immunocompetence; Levofloxacin; Mice; Microbial Sensitivity Tests; Mutation; Neutropenia; Ofloxacin; Plague; Selection, Genetic; Streptomycin; Thigh; Treatment Outcome; Yersinia pestis | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
Water-soluble pleuromutilin derivative with excellent in vitro and in vivo antibacterial activity against gram-positive pathogens.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Molecular Structure; Pleuromutilins; Polycyclic Compounds; Solubility; Stereoisomerism; Water | 2008 |
Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Disease Models, Animal; Drug Resistance, Bacterial; Female; Humans; Methicillin Resistance; Mice; Mice, Inbred BALB C; Phenotype; Pneumonia, Staphylococcal; Staphylococcus aureus | 2008 |
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
Topics: Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Epithelium; Female; Levofloxacin; Mice; Ofloxacin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Female; Levofloxacin; Lung Diseases; Mice; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2009 |
Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.
Topics: Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Bacteria; Disease Models, Animal; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Staphylococcal Infections; Structure-Activity Relationship; Topoisomerase II Inhibitors; Urea | 2013 |
Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).
Topics: Adenosine Triphosphatases; Amides; Animals; Anti-Bacterial Agents; Crystallography, X-Ray; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Knockout; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrroles; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2014 |
Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridines | 2017 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Determination of the Postexposure Prophylactic Benefit of Oral Azithromycin and Clarithromycin Against Inhalation Anthrax in Cynomolgus Macaques.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Azithromycin; Bacillus anthracis; Clarithromycin; Disease Models, Animal; Levofloxacin; Macaca fascicularis; Respiratory Tract Infections | 2022 |
Hydrophilic and degradable polyesters based on l-aspartic acid with antibacterial properties for potential application in hernia repair.
Topics: Animals; Anti-Bacterial Agents; Aspartic Acid; Cell Line; Disease Models, Animal; Escherichia coli; Herniorrhaphy; Hydrophobic and Hydrophilic Interactions; Levofloxacin; Mice; Polyesters; Staphylococcus aureus; Wound Healing | 2019 |
DAV131A Protects Hamsters from Lethal
Topics: Administration, Oral; Adsorption; Animals; Anti-Bacterial Agents; Charcoal; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; Disease Models, Animal; Dysbiosis; Fluoroquinolones; Gastrointestinal Microbiome; Levofloxacin; Male; Mesocricetus | 2019 |
Eye drops and eye gels of levofloxacin: comparison of ocular absorption characterizations and therapeutic effects in the treatment of bacterial keratitis in rabbits.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Gels; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Ocular Absorption; Ophthalmic Solutions; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 2020 |
The African Green Monkey Model of Pneumonic Plague and US Food and Drug Administration Approval of Antimicrobials Under the Animal Rule.
Topics: Animals; Chlorocebus aethiops; Disease Models, Animal; Levofloxacin; Plague; United States; United States Food and Drug Administration; Yersinia pestis | 2020 |
Effect of Delaying Treatment on Efficacy of Ciprofloxacin and Levofloxacin in the African Green Monkey Model of Pneumonic Plague.
Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Ciprofloxacin; Disease Models, Animal; Levofloxacin; Plague; Yersinia pestis | 2020 |
Potent synergistic combination of rosuvastatin and levofloxacin against Staphylococcus aureus: in vitro and in vivo study.
Topics: Animals; Anti-Bacterial Agents; Bacterial Toxins; Biofilms; Coagulase; Disease Models, Animal; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Hemolysin Proteins; Levofloxacin; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Rosuvastatin Calcium; Sphingomyelin Phosphodiesterase; Staphylococcal Infections; Staphylococcus aureus; Virulence Factors; Wound Infection | 2021 |
Tea polyphenols and Levofloxacin alleviate the lung injury of hepatopulmonary syndrome in common bile duct ligation rats through Endotoxin -TNF signaling.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacterial Translocation; Camellia sinensis; Common Bile Duct; Disease Models, Animal; Endotoxins; Hepatopulmonary Syndrome; Levofloxacin; Ligation; Lung; Lung Injury; Male; Polyphenols; Protein Interaction Maps; Rats, Sprague-Dawley; Signal Transduction; Tumor Necrosis Factor-alpha | 2021 |
Development of a dual delivery of levofloxacin and prednisolone acetate via PLGA nanoparticles/ thermosensitive chitosan-based hydrogel for postoperative management: An in-vitro and ex-vivo study.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cell Survival; Cells, Cultured; Chitosan; Cytokines; Disease Models, Animal; Drug Carriers; Drug Liberation; Drug Therapy, Combination; Endophthalmitis; Epithelial Cells; Epithelium, Corneal; Hydrogels; Keratitis; Levofloxacin; Nanoparticles; Particle Size; Postoperative Complications; Prednisolone; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Temperature | 2021 |
A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.
Topics: Amikacin; Animals; Antigens, Bacterial; Antitubercular Agents; BCG Vaccine; Disease Models, Animal; Drug Resistance, Bacterial; Levofloxacin; Mice, Inbred BALB C; Mice, SCID; Mycobacterium bovis; Mycobacterium tuberculosis; Plasmids; Prothionamide; Pyrazinamide; Tuberculosis, Pulmonary; Vaccines, Synthetic; Virulence | 2021 |
Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Levofloxacin; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Treatment Outcome | 2017 |
Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Disease Models, Animal; Ertapenem; Escherichia coli Infections; Female; Humans; Levofloxacin; Mice, Inbred ICR; Microbial Sensitivity Tests; Urinary Tract Infections; Uropathogenic Escherichia coli | 2017 |
Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Azetidines; Cefepime; Cefiderocol; Cephalosporins; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Female; Humans; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Monobactams; Pseudomonas aeruginosa; Pyridones; Siderophores; Sulfonamides | 2018 |
Treating Anthrax-Induced Meningitis in Rabbits.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antitoxins; Bacillus anthracis; Central Nervous System; Ciprofloxacin; Clindamycin; Dexamethasone; Disease Models, Animal; Drug Combinations; Imipenem; Levofloxacin; Linezolid; Meningitis, Bacterial; Meropenem; Rabbits; Treatment Failure | 2018 |
Ameliorative effects of
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Chemical and Drug Induced Liver Injury; Cytoprotection; Disease Models, Animal; Inflammation Mediators; Interleukin-1; Interleukin-10; Levofloxacin; Liver; Male; Moringa oleifera; Oxidative Stress; Plant Extracts; Plant Leaves; Rats, Wistar | 2020 |
[Justification of a use of additional antioxidant therapy in experimental models of chronic bacterial prostatitis].
Topics: Adult; Animals; Anti-Bacterial Agents; Antioxidants; Bacterial Infections; Disease Models, Animal; Humans; Levofloxacin; Lipid Peroxidation; Male; Oxidative Stress; Prostatitis; Rats; Superoxide Dismutase | 2019 |
Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Levofloxacin; Mice; Mice, Inbred C57BL; Mutant Proteins; Pneumonia, Bacterial; Treatment Outcome | 2013 |
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Levofloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis | 2013 |
Levofloxacin decreased chest wall mechanical inhomogeneities and airway and vascular remodeling in rats with induced hepatopulmonary syndrome.
Topics: Airway Remodeling; Animals; Cholestasis; Disease Models, Animal; Hepatopulmonary Syndrome; Levofloxacin; Lung; Male; Membrane Proteins; Pulmonary Artery; Rats; Rats, Wistar; Respiratory Muscles; Statistics, Nonparametric; Thoracic Wall; Topoisomerase II Inhibitors | 2013 |
Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Levofloxacin; Microbial Sensitivity Tests; Rabbits; Soft Tissue Infections | 2014 |
Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model.
Topics: Animals; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Disease Models, Animal; Doripenem; Ertapenem; Humans; Klebsiella pneumoniae; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests | 2014 |
Preparation of levofloxacin thermo-sensitive gel and clinical application in the treatment of suppurative otitis media.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Eosine Yellowish-(YS); Gels; Hematoxylin; Levofloxacin; Male; Otitis Media, Suppurative; Poloxamer; Rats, Sprague-Dawley | 2014 |
Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Cationic Peptides; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Eye Infections, Bacterial; Gentamicins; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 2014 |
In vivo challenging of polymyxins and levofloxacin eye drop against multidrug-resistant Pseudomonas aeruginosa keratitis.
Topics: Animals; Anti-Bacterial Agents; Colistin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Keratitis; Levofloxacin; Male; Microbial Sensitivity Tests; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 2014 |
In vitro and in vivo effectiveness evaluation of balofloxacin in experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Ophthalmic Solutions; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 2014 |
Levofloxacin-ceftriaxone combination attenuates lung inflammation in a mouse model of bacteremic pneumonia caused by multidrug-resistant Streptococcus pneumoniae via inhibition of cytolytic activities of pneumolysin and autolysin.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; Bronchoalveolar Lavage Fluid; Ceftriaxone; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Levofloxacin; Male; Mice; Mice, Inbred BALB C; N-Acetylmuramoyl-L-alanine Amidase; Pneumococcal Infections; Pneumonia; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Streptolysins; Virulence; Virulence Factors | 2014 |
Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax.
Topics: Animals; Anthrax; Anti-Bacterial Agents; Antigens, Bacterial; Bacillus anthracis; Bacteremia; Disease Models, Animal; Drug Therapy, Combination; Female; Immunoglobulins, Intravenous; Levofloxacin; Male; Rabbits; Respiratory Tract Infections; Toxemia; Treatment Outcome | 2014 |
Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Meropenem; Mice; Microbial Sensitivity Tests; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2015 |
Combined immunomodulator and antimicrobial therapy eliminates polymicrobial sepsis and modulates cytokine production in combined injured mice.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Bacterial Infections; Chemokines; Cord Factors; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Female; Gamma Rays; Growth Substances; Immunologic Factors; Levofloxacin; Lipid A; Mice; Radiation Injuries, Experimental; Sepsis; Skin; Wound Infection | 2015 |
Daptomycin combinations as alternative therapies in experimental foreign-body infection caused by meticillin-susceptible Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Complementary Therapies; Daptomycin; Disease Models, Animal; Drug Therapy, Combination; Foreign Bodies; Levofloxacin; Male; Rats, Wistar; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2015 |
Effects of Fluoroquinolone-Based Antibacterial Ophthalmic Solutions on Corneal Wound Healing.
Topics: Animals; Anti-Bacterial Agents; Cell Proliferation; Cell Survival; Corneal Injuries; Disease Models, Animal; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Rabbits; Time Factors; Wound Healing | 2015 |
Investigation of the Role of Bacteria in the Development of Acanthamoeba Keratitis.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Anti-Bacterial Agents; Bacterial Physiological Phenomena; Disease Models, Animal; DNA, Bacterial; DNA, Protozoan; Escherichia coli; Eye Infections, Parasitic; Fluorescent Dyes; Humans; Levofloxacin; Microscopy, Electron; Organic Chemicals; Rabbits; Real-Time Polymerase Chain Reaction; RNA, Ribosomal, 16S; RNA, Ribosomal, 18S | 2015 |
Two Different Concentrations of Topical Levofloxacin for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Keratitis.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Keratitis; Levofloxacin; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits | 2015 |
The antibacterial activity of levofloxacin eye drops against staphylococci using an in vitro pharmacokinetic model in the bulbar conjunctiva.
Topics: Animals; Anti-Bacterial Agents; Conjunctiva; Conjunctivitis, Bacterial; Disease Models, Animal; Drug Resistance, Bacterial; Levofloxacin; Male; Ophthalmic Solutions; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Staphylococcus epidermidis | 2016 |
A Bioluminescent Francisella tularensis SCHU S4 Strain Enables Noninvasive Tracking of Bacterial Dissemination and the Evaluation of Antibiotics in an Inhalational Mouse Model of Tularemia.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Francisella tularensis; Levofloxacin; Liver; Luminescent Measurements; Lymph Nodes; Mice; Mice, Inbred BALB C; Spleen; Tularemia | 2016 |
Number of Bacteria and Time of Coincubation With Bacteria Required for the Development of Acanthamoeba Keratitis.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Physiological Phenomena; Disease Models, Animal; Eye Infections, Parasitic; Levofloxacin; Pseudomonas aeruginosa; Rabbits; Time Factors | 2017 |
In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model.
Topics: Animals; Bacteria, Anaerobic; Disease Models, Animal; Fluoroquinolones; Fusobacterium necrophorum; Levofloxacin; Liver; Liver Abscess; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests | 2017 |
Levofloxacin loaded mesoporous silica microspheres/nano-hydroxyapatite/polyurethane composite scaffold for the treatment of chronic osteomyelitis with bone defects.
Topics: Absorbable Implants; Animals; Bone and Bones; Bone Regeneration; Chronic Disease; Disease Models, Animal; Durapatite; Immunohistochemistry; Levofloxacin; Microspheres; Nanoparticles; Osteomyelitis; Polyurethanes; Rabbits; Radiography; Silicon Dioxide; Tissue Scaffolds; X-Ray Microtomography | 2017 |
Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Humans; Knee Prosthesis; Levofloxacin; Methicillin; Microbial Sensitivity Tests; Ofloxacin; Prosthesis-Related Infections; Rabbits; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2009 |
Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Cloxacillin; Colony Count, Microbial; Cytoplasm; Disease Models, Animal; Foreign Bodies; Levofloxacin; Ofloxacin; Rats; Staphylococcal Infections; Staphylococcus aureus | 2009 |
[Efficacy of levofloxacin, lomefloxacin and moxifloxacin vs. other fluoroquinolones in experimental plague due to FI+ and FI- strains of Yersinia pestis in Albino mice].
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Mice; Moxifloxacin; Ofloxacin; Plague; Quinolines; Species Specificity; Time Factors; Yersinia pestis | 2009 |
[Therapeutic efficacy of levofloxacin against a model of replicable Legionella pneumophila lung infection in DBA/2 mice].
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Bacterial; Female; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Mice; Mice, Inbred DBA; Microbial Sensitivity Tests; Ofloxacin; Treatment Outcome | 2009 |
Efficacy of antimicrobial polymer coatings in an animal model of bacterial infection associated with foreign body implants.
Topics: Animals; Anti-Bacterial Agents; Colony Count, Microbial; Disease Models, Animal; Female; Foreign Bodies; Humans; Levofloxacin; Mice; Mice, Inbred BALB C; Ofloxacin; Polymers; Prosthesis-Related Infections; Staphylococcal Infections; Staphylococcus aureus | 2010 |
Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Drug Resistance, Bacterial; Eye Infections, Bacterial; Levofloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tobramycin; Vancomycin | 2010 |
Novel mucoadhesive polysaccharide isolated from Bletilla striata improves the intraocular penetration and efficacy of levofloxacin in the topical treatment of experimental bacterial keratitis.
Topics: Absorption; Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Bacterial Load; Biological Availability; Cell Line; Cell Proliferation; Cornea; Disease Models, Animal; Endothelial Cells; Eye; Female; Humans; Keratitis; Levofloxacin; Male; Ofloxacin; Ophthalmic Solutions; Orchidaceae; Plant Extracts; Polysaccharides; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Tears; Treatment Outcome | 2010 |
In vitro intracellular activity and in vivo efficacy of modithromycin, a novel bicyclolide, against Legionella pneumophila.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Bridged-Ring Compounds; Cell Line; Cells, Cultured; Clarithromycin; Disease Models, Animal; Humans; Ketolides; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Macrolides; Mice; Microbial Sensitivity Tests; Ofloxacin | 2011 |
Levofloxacin cures experimental pneumonic plague in African green monkeys.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Chlorocebus aethiops; Disease Models, Animal; Infusions, Intravenous; Levofloxacin; Lung; Ofloxacin; Plague; Primate Diseases; Radiography, Thoracic; Survival Analysis | 2011 |
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Space; Fluoroquinolones; Intracellular Space; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Peritonitis; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2012 |
[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].
Topics: Animals; Antibiotics, Antitubercular; Disease Models, Animal; Drug Therapy, Combination; Drug Tolerance; Fluoroquinolones; Gatifloxacin; Isoxazoles; Levofloxacin; Mice; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Rifabutin; Tuberculosis | 2011 |
Critical appraisal of air pouch infection model in rats.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Exudates and Transudates; Female; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rats; Rats, Wistar; Staphylococcus aureus; Vancomycin | 2012 |
A peptide based on homologous sequences of the β-barrel assembly machinery component BamD potentiates antibiotic susceptibility of Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Bacterial Outer Membrane Proteins; Blotting, Western; Colistin; Disease Models, Animal; Drug Therapy, Combination; Electrophoresis, Polyacrylamide Gel; Female; Levofloxacin; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Ofloxacin; Peptides; Pneumonia, Bacterial; Protein Binding; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2012 |
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
Topics: Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antigens, Bacterial; Bacterial Toxins; Disease Models, Animal; Drug Therapy, Combination; Humans; Immunoglobulin G; Levofloxacin; Ofloxacin; Post-Exposure Prophylaxis; Rabbits; Recombinant Proteins; Respiratory Tract Infections; Survival Analysis; Treatment Outcome; Vaccination | 2012 |
[Protection and mechanism of Fagopyrum cymosum on lung injury in rats with Klebsiella pneumonia].
Topics: Animals; Chemokine CXCL2; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Fagopyrum; Immunohistochemistry; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Lung; Male; Ofloxacin; Pneumonia, Bacterial; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2012 |
A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.
Topics: Animals; Animals, Outbred Strains; Anti-Bacterial Agents; Disease Models, Animal; Female; Flow Cytometry; Genes, Reporter; Humans; Levofloxacin; Luciferases; Mice; Microscopy, Fluorescence; Molecular Imaging; Ofloxacin; Plague; Virulence; Yersinia pestis | 2013 |
Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aphakia, Postcataract; Aza Compounds; Disease Models, Animal; Electroretinography; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Fluoroquinolones; Gram-Positive Bacterial Infections; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Rabbits; Time Factors | 2013 |
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
Topics: Adjuvants, Immunologic; Administration, Inhalation; Animals; Anthrax; Anthrax Vaccines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Bacterial; Bacillus anthracis; Bacterial Toxins; Disease Models, Animal; Female; Kinetics; Levofloxacin; Male; Ofloxacin; Rabbits; Spores, Bacterial; Survival Analysis | 2013 |
Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Genotype; Humans; Levofloxacin; Lung; Male; Microbial Sensitivity Tests; Mutation; Ofloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Pulmonary Edema; Rabbits; Spleen; Streptococcus pneumoniae | 2002 |
Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Disease Models, Animal; Doxycycline; Drug Therapy, Combination; Injections, Intraperitoneal; Levofloxacin; Male; Ofloxacin; Polyesters; Prosthesis-Related Infections; Rats; Staphylococcal Infections; Staphylococcus epidermidis; Virginiamycin | 2002 |
Reply to: Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Disease Models, Animal; Levofloxacin; Ofloxacin; Penicillin Resistance; Pneumonia, Pneumococcal; Quinolones; Rabbits; Streptococcus pneumoniae | 2003 |
Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Colony Count, Microbial; Disease Models, Animal; Escherichia coli Infections; Escherichia coli O157; Feces; Levofloxacin; Male; Mice; Mice, Inbred C3H; Miocamycin; Ofloxacin; Survival Analysis | 2003 |
Fluoroquinolone therapy in multiple-drug resistant staphylococcal keratitis after lamellar keratectomy in a rabbit model.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Keratomileusis, Laser In Situ; Levofloxacin; Ofloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2003 |
Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis.
Topics: Animals; Disease Models, Animal; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Levofloxacin; Male; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Ofloxacin; Penicillin Resistance; Polymerase Chain Reaction; Rabbits; Reference Values; Sensitivity and Specificity; Streptococcus pneumoniae; Thienamycins | 2003 |
Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Topics: Abdominal Abscess; Animals; Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Clindamycin; Disease Models, Animal; Fluoroquinolones; Injections, Subcutaneous; Levofloxacin; Male; Metronidazole; Mice; Moxifloxacin; Ofloxacin; Quinolines | 2004 |
Novel murine model of pneumococcal pneumonia: use of temperature as a measure of disease severity to compare the efficacies of moxifloxacin and levofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Body Temperature; Colony Count, Microbial; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Moxifloxacin; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Skin Temperature | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Cornea; Corneal Transplantation; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratitis; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Rabbits | 2005 |
In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Ceftazidime; Disease Models, Animal; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Sensitivity and Specificity | 2005 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mice; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Survival Analysis | 2006 |
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacterial Outer Membrane Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Gene Deletion; Genes, Bacterial; Levofloxacin; Male; Membrane Proteins; Membrane Transport Proteins; Mice; Microbial Sensitivity Tests; Neutropenia; Ofloxacin; Pseudomonas aeruginosa; Sepsis | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cloxacillin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Foreign-Body Reaction; Humans; Levofloxacin; Linezolid; Male; Methicillin; Microbial Sensitivity Tests; Ofloxacin; Oxazolidinones; Rats; Rats, Wistar; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2006 |
[Comparative study of treatment with quinupristin-dalfopristin alone or in combination with gentamicin, teicoplanin, imipenem or levofloxacin in experimental endocarditis due to a multidrug-resistant Enterococcus faecium].
Topics: Aged; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecium; Female; Gentamicins; Gram-Positive Bacterial Infections; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Rabbits; Teicoplanin; Virginiamycin | 2006 |
Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis.
Topics: Aged; Anaplasma phagocytophilum; Anaplasmosis; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Humans; Levofloxacin; Male; Mice; Mice, SCID; Ofloxacin; Recurrence; Treatment Outcome | 2006 |
Short-course therapy of gemifloxacin effective against pneumococcal pneumonia in mice.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Body Temperature; Colony Count, Microbial; Disease Models, Animal; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Lung; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Mutation, Missense; Naphthyridines; Ofloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome | 2006 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes | 2007 |
Role of interleukin-6 in the pathogenesis of an avian model of Staphylococcus aureus arthritis.
Topics: Animals; Anti-Bacterial Agents; Arthritis, Infectious; Chickens; Disease Models, Animal; Interleukin-6; Levofloxacin; Ofloxacin; Staphylococcal Infections; Staphylococcus aureus | 2007 |
Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha.
Topics: Alanine Transaminase; Animals; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Etanercept; Fluoroquinolones; Immunoglobulin G; Inflammation; Levofloxacin; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Naphthyridines; Ofloxacin; Pentoxifylline; Receptors, Tumor Necrosis Factor; Time Factors; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2007 |
Simultaneous determination of rifampicin and levofloxacin concentrations in catheter segments from a mouse model of a device-related infection by liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: Animals; Anti-Bacterial Agents; Catheters, Indwelling; Chromatography, High Pressure Liquid; Disease Models, Animal; Levofloxacin; Mice; Mice, Inbred BALB C; Ofloxacin; Rifampin; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Staphylococcus aureus | 2008 |
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Fluoroquinolones; Levofloxacin; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Distress Syndrome | 2008 |
Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague.
Topics: Animals; Anti-Bacterial Agents; Cytokines; Disease Models, Animal; Female; Levofloxacin; Lipoproteins; Macrophages; Mice; Mice, Inbred BALB C; Mutation; Ofloxacin; Plague; Virulence; Virulence Factors; Yersinia pestis; Yersinia pseudotuberculosis | 2008 |
Activity of levofloxacin in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Culture Media; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Levofloxacin; Lung; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Ofloxacin; Quinolones; Spleen; Stereoisomerism; Tuberculosis, Pulmonary | 1994 |
Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.
Topics: Animals; Anti-Infective Agents; Bacteroides fragilis; Disease Models, Animal; Drug Therapy, Combination; Endometritis; Escherichia coli; Female; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Rats; Rats, Sprague-Dawley | 1998 |
Successful treatment of murine listeriosis and salmonellosis with levofloxacin.
Topics: Animals; Anti-Infective Agents; Cephalosporins; Disease Models, Animal; Dose-Response Relationship, Drug; Levofloxacin; Listeria monocytogenes; Listeriosis; Mice; Ofloxacin; Penicillins; Salmonella Infections, Animal; Salmonella typhimurium | 1998 |
Prophylaxis of local vascular graft infection with levofloxacin incorporated into albumin-sealed dacron graft (LVFX-ALB Graft).
Topics: Albumins; Animals; Anti-Infective Agents; Bacterial Adhesion; Blood Vessel Prosthesis Implantation; Colony Count, Microbial; Disease Models, Animal; Dogs; Humans; Levofloxacin; Ofloxacin; Polyethylene Terephthalates; Rabbits; Staphylococcal Infections | 1999 |
Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia.
Topics: Acute Kidney Injury; Administration, Cutaneous; Animals; Anti-Infective Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Drug Resistance, Microbial; Humans; Lethal Dose 50; Levofloxacin; Mice; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Pneumococcal Infections; Streptococcus pneumoniae; Survival Analysis; Time Factors; Uranyl Nitrate | 1999 |
Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Toxins; Diarrhea; Disease Models, Animal; Escherichia coli Infections; Escherichia coli O157; Feces; Fosfomycin; Germ-Free Life; Humans; Levofloxacin; Mice; Ofloxacin; Shiga Toxins; Treatment Outcome | 2000 |
Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation.
Topics: Animals; Biofilms; Chronic Disease; Clarithromycin; Disease Models, Animal; Drug Therapy, Combination; Intubation; Levofloxacin; Male; Mice; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2000 |
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia.
Topics: Acinetobacter Infections; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Drug Therapy, Combination; Female; Imipenem; Levofloxacin; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Bacterial; Thienamycins | 2000 |
Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Female; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Rabbits; Streptococcus pneumoniae | 2001 |
Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Disease Models, Animal; Levofloxacin; Meningitis, Pneumococcal; Ofloxacin; Rabbits; Streptococcus pneumoniae | 2001 |
Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Disease Models, Animal; Escherichia coli Infections; Escherichia coli O157; Female; Germ-Free Life; Immunoglobulin G; Kidney; Levofloxacin; Male; Mice; Ofloxacin; Shiga Toxin; Survival Analysis; Time Factors; Tumor Necrosis Factor-alpha | 2001 |
Therapeutic efficacy of intraperitoneal polymyxin B and polymyxin-like peptides alone or combined with levofloxacin in rat models of septic shock.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Disease Models, Animal; Drug Therapy, Combination; Injections, Intraperitoneal; Levofloxacin; Male; Ofloxacin; Polymyxin B; Rats; Rats, Wistar; Shock, Septic | 2002 |
In vitro and in vivo activities of ciprofloxacin and levofloxacin against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.
Topics: Animals; Anti-Infective Agents; beta-Lactamases; Ciprofloxacin; Colony Count, Microbial; Disease Models, Animal; Klebsiella Infections; Klebsiella pneumoniae; Levofloxacin; Male; Mice; Mice, Inbred Strains; Microbial Sensitivity Tests; Ofloxacin | 2002 |
Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Disease Models, Animal; Fluoroquinolones; Foreign-Body Reaction; Guinea Pigs; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Ofloxacin; Rats; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2002 |